摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-氯-1-(2,4-二甲氧基苄基)-6-氟-4-氧代-1,4-二氢[1,8]萘啶-3-羧酸乙酯 | 110286-57-2

中文名称
7-氯-1-(2,4-二甲氧基苄基)-6-氟-4-氧代-1,4-二氢[1,8]萘啶-3-羧酸乙酯
中文别名
——
英文名称
7-chloro-1-(2,4-dimethoxybenzyl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid ethyl ester
英文别名
Ethyl 7-chloro-1-(2,4-dimethoxybenzyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate;ethyl 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylate
7-氯-1-(2,4-二甲氧基苄基)-6-氟-4-氧代-1,4-二氢[1,8]萘啶-3-羧酸乙酯化学式
CAS
110286-57-2
化学式
C20H18ClFN2O5
mdl
——
分子量
420.825
InChiKey
ALGFEPRPPFDZCL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    146-147 °C
  • 沸点:
    582.4±50.0 °C(Predicted)
  • 密度:
    1.380±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    29
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    78
  • 氢给体数:
    0
  • 氢受体数:
    8

SDS

SDS:fc7c880a1840149a39e1faea3518191a
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4

反应信息

  • 作为反应物:
    描述:
    7-氯-1-(2,4-二甲氧基苄基)-6-氟-4-氧代-1,4-二氢[1,8]萘啶-3-羧酸乙酯 在 lithium hydroxide 、 二异丁基氢化铝 、 sodium cyanoborohydride 、 potassium carbonate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 溶剂黄146N,N-二异丙基乙胺 作用下, 以 甲醇乙醇二氯甲烷氯仿 为溶剂, 反应 16.0h, 生成 1-(2,4-Dimethoxy-benzyl)-6-fluoro-3-phenylaminomethyl-7-pyrrolidin-1-yl-1H-[1,8]naphthyridin-4-one
    参考文献:
    名称:
    Novel inhibitors of bacterial protein synthesis: structure–activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants
    摘要:
    Structure-activity relationships for a recently discovered novel ribosome inhibitor (NRI) class of antibacterials were investigated. Preliminary efforts to optimize protein synthesis inhibitory activity of the series through modification of positions 3 and 4 of the naphthyridone lead template resulted in the identification of several biochemically potent analogues. A lack of corresponding whole cell antibacterial activity is thought to be a consequence of poor cellular penetration as evidenced by the enhancement of activity observed for a lead analogue tested in the presence of a cell permeabilizing agent. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.03.091
  • 作为产物:
    参考文献:
    名称:
    在尝试合成吡啶并ze庚酮羧酸时遇到的重排。
    摘要:
    尝试通过标准方法合成吡啶基ze庚酮羧酸(如33)仅导致异常和意想不到的重排产物。尝试通过六元环的扩环和羟醛环的闭合来形成七元环。在每种情况下,主要产品都是由于未检测到所需产品而对原料进行了重排而产生的。最终,制备了吡啶并ze庚酮乙酯的异构体。然而,尝试皂化导致了另一种异常的重新排列。[反应:看文字]
    DOI:
    10.1021/ol0481378
点击查看最新优质反应信息

文献信息

  • Antibacterial compounds
    申请人:——
    公开号:US20030232818A1
    公开(公告)日:2003-12-18
    Antibacterials having formula (I) 1 and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.
    抗菌剂的化学式(I)及其盐、前药、前药的盐,制备这些化合物的方法和用于制备过程中使用的中间体,含有这些化合物的组合物,以及使用这些化合物进行细菌感染的预防和治疗方法被披露。
  • Naphthyridine-based antibacterial compositions
    申请人:Abbott Laboratories
    公开号:US07632946B2
    公开(公告)日:2009-12-15
    Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.
    本发明公开了具有式(I)及其盐、前药和前药的盐,用于抑制细菌蛋白质合成的化合物,以及制造该化合物的过程和该过程中的中间体,含有该化合物的组合物和使用该化合物的方法。
  • Novel Antibacterial Class:  A Series of Tetracyclic Derivatives
    作者:Mira M. Hinman、Teresa A. Rosenberg、Darlene Balli、Candace Black-Schaefer、Linda E. Chovan、Douglas Kalvin、Philip J. Merta、Angela M. Nilius、Steve D. Pratt、Niru B. Soni、Frank L. Wagenaar、Moshe Weitzberg、Rolf Wagner、Bruce A. Beutel
    DOI:10.1021/jm060010w
    日期:2006.8.1
    We describe the synthesis and antibacterial activity of a series of tetracyclic naphthyridones. The members of this series act primarily via inhibition of bacterial translation and belong to the class of novel ribosome inhibitors (NRIs). In this paper we explore the structure-activity relationships (SAR) of these compounds to measure their ability both to inhibit bacterial translation and also to inhibit the growth of bacterial cells in culture. The most active of these compounds inhibit Streptococcus pneumoniae translation at concentrations of < 5 mu M and have minimum inhibitory concentrations (MICs) of < 8 mu g/mL against clinically relevant strains of bacteria.
  • NARITA, XIROKADZU;KONISI, JOSINORI;NITTA, DZYUN;TAKAGI, XIROIKU;IINO, FUM+
    作者:NARITA, XIROKADZU、KONISI, JOSINORI、NITTA, DZYUN、TAKAGI, XIROIKU、IINO, FUM+
    DOI:——
    日期:——
  • US7135468B2
    申请人:——
    公开号:US7135468B2
    公开(公告)日:2006-11-14
查看更多